


# Q1 Which stakeholder group would you self-identify as part of?

Answered: 52 Skipped: 0




ANSWER CHOICES	RESPONSES	
Agency Staff (HTA producer)	32.69%	17
Clinician, Nurse Practitioners	9.62%	5
Industry Representative, Technology Innovators	11.54%	6
Organizational Partner Representative	3.85%	2
Patient Group Representative, Patient Advocate, Patient, Family Member, Caregiver, Citizen	0.00%	0
Payer, Policy Decision-Maker	3.85%	2
Research Funding Agency Representative	0.00%	0
Researcher (Academic, non-agency based), Clinical Reviewer, Guideline Developer	25.00%	13
Trialist, Primary Evidence Producer	1.92%	1
Other (please specify)	11.54%	6
<b>TOTAL</b>		<b>52</b>

## Understanding the Effect of COVID-19 on HTA Globally

#	OTHER (PLEASE SPECIFY)	DATE
1	Consultant	5/17/2020 6:42 AM
2	I am in charge of the NRA and the HTA agency in my country	5/15/2020 8:14 AM
3	Federal officde HTA commisioner	5/14/2020 2:22 AM
4	Hospital assessment of innovations/HTA	5/14/2020 2:14 AM
5	Guideline developer and publisher	5/14/2020 12:58 AM
6	HTAi Secretariat	5/13/2020 10:18 PM

### Q3 How many years have you been working in HTA, or a similar field?


Answered: 52 Skipped: 0



ANSWER CHOICES	RESPONSES	
Less than 5 years (Early Career)	7.69%	4
5-8 years	19.23%	10
9-15 years	32.69%	17
15 years +	40.38%	21
<b>TOTAL</b>		<b>52</b>

## Q5 What type of healthcare system does your country operate?

Answered: 52 Skipped: 0




ANSWER CHOICES	RESPONSES	
Public Welfare system	44.23%	23
Insurance based, Private System	26.92%	14
Mixed Public/ Private System	53.85%	28
Centralized	23.08%	12
Decentralized	23.08%	12
Unsure	0.00%	0
Other (please specify)	9.62%	5
Total Respondents: 52		

#	OTHER (PLEASE SPECIFY)	DATE
1	Since 2007 we have a National Health System with public and private providers	5/15/2020 8:14 AM
2	Mixed. Tax-based/social health insurance-based	5/15/2020 6:01 AM
3	Mixed centralized/decentralized	5/14/2020 12:09 AM
4	Self-pay	5/13/2020 8:36 PM
5	Fragmented	5/13/2020 5:38 PM

## Q6 Are there any initiatives such as HTA or evidence-based decision making in your healthcare sector? \*

Answered: 51 Skipped: 1




ANSWER CHOICES	RESPONSES	
Yes	84.31%	43
No	5.88%	3
Other (please specify)	9.80%	5
<b>TOTAL</b>		<b>51</b>

#	OTHER (PLEASE SPECIFY)	DATE
1	We are in the process of implementing an HTA agency	5/17/2020 6:42 AM
2	On the National level there is CONETEC (National Commission on HTA) and RedArets (HTA public network). I am part of both. As the country is federal, every province makes it's own decisions on technologies. That's why the network was created in 2012, were 14 provinces share their reports and some reports are made colaboratively between provinces	5/16/2020 6:23 AM
3	clinical experimentation on possible drugs' efficacy on Covid patients	5/15/2020 10:52 AM
4	Very limited, and mostly not relevant.	5/15/2020 7:25 AM
5	very little - mainly centralized for Drugs, something at regional level for devices	5/15/2020 6:59 AM

## Q8 How has COVID-19 affected your work?

Answered: 52 Skipped: 0




ANSWER CHOICES	RESPONSES	
Decrease in support for non-COVID items	11.54%	6
Increase in workload for COVID related items	42.31%	22
Increase in workload overall	32.69%	17
Decrease in workload overall	3.85%	2
COVID has had no affect on my work	5.77%	3
Other (please specify)	3.85%	2
<b>TOTAL</b>		<b>52</b>

#	OTHER (PLEASE SPECIFY)	DATE
1	logistics, projects envisaging interviews with experts, decision makers etc. slowed down	5/15/2020 6:59 AM
2	In lockdown in Southern France. Any work by internet.	5/13/2020 10:27 PM

## Q9 Are you aware of any ongoing COVID-19 initiatives related to HTA or evidence based decision making in your country?

Answered: 52 Skipped: 0



ANSWER CHOICES	RESPONSES	
Compilation of evidence/inventory/resources/evidence maps	61.54%	32
Rapid assessments/evidence synthesis on diagnostic tests	57.69%	30
Rapid assessments/evidence synthesis of pharmaceuticals	53.85%	28
Rapid assessments/evidence synthesis on vaccines	30.77%	16
Public Health Guidance Development	63.46%	33
Methodological Guidelines/ position statements	42.31%	22
Patient related information	46.15%	24
Other (please specify)	21.15%	11
Total Respondents: 52		

## Understanding the Effect of COVID-19 on HTA Globally

#	OTHER (PLEASE SPECIFY)	DATE
1	New telehealth services and fees, Covid diagnostic fees	5/21/2020 12:57 AM
2	hackathons being organised by both MoH and Ministry of Science, Technology, Innovation and Communication of Brazil	5/18/2020 8:24 AM
3	Mathematical predictive models	5/16/2020 6:23 AM
4	A few economic analyses are being undertaken.	5/15/2020 7:25 AM
5	Whatever is being done is mostly by individual researchers and health institution	5/15/2020 7:08 AM
6	No	5/15/2020 6:21 AM
7	Use of innovation technology like Artificial Inteligence for diagnosis of Covid using chest image of TAC	5/14/2020 9:45 AM
8	Analysis of adopted organizational models at Regional/Local level	5/14/2020 12:40 AM
9	Support for COVID Patent Pool	5/13/2020 10:27 PM
10	<a href="https://www.albertahealthservices.ca/topics/Page17074.aspx">https://www.albertahealthservices.ca/topics/Page17074.aspx</a>	5/13/2020 10:18 PM
11	Evaluating effectiveness and safety of convalescent plasma and pathogen reduction technology	5/13/2020 7:49 PM

Q10 When you think about the global evidence community (from bench to bedside) and our shared response to COVID-19 today, what's keeping you up at night?


#	RESPONSES	DATE
1	too many and quick "scientific" information published....credibility?	5/21/2020 1:20 AM
2	Global supply chain, regulatory and pricing of future vaccines and antiviral therapies. How do we ensure fair and equitable access?	5/21/2020 12:57 AM
3		5/20/2020 7:18 PM
4	...	5/18/2020 2:38 PM
5	frankly to say, the chores at home don't make me to keep up at night. however, some thoughts like when will it end, why officials didn't do this instead of that, why in dictatorship countries HTA&EBM are implausible and so on.	5/18/2020 12:12 PM
6	Patients and the increasing death rates, as well as infodemia and the amount of messages I receive everyday to clarify misconceptions fake news and wrong news, everyday!	5/18/2020 8:24 AM
7	The lack of adequately equipped healthcare facilities; the absence of health systems to help in adequate planning	5/17/2020 6:42 AM
8	Monitoring and forecast for infection threats	5/17/2020 2:37 AM
9	development of an effective vaccine and effective life saving medication.	5/15/2020 9:45 AM
10	A primary sensitive issue that we bring here is linked to the relationship between the social isolation and its economic impact. This aspect warns us specially in the sense of understanding how the pandemic will affect the possibilities of sustaining public health policies in medium and long term. In addition, social disparities and inequities are also being intensified at the moment. This situation has an impact not only on the course of the pandemic in the different socio-cultural contexts, but also on the quality of life and survival of these populations. In this sense, we highlight the imperative to develop and implement a set of policies for social protection and support for vulnerable populations, so that we can ensure the sustainability and effectiveness of social distance measures.	5/15/2020 9:41 AM
11	A primary sensitive issue that we bring here is linked to the relationship between the social isolation and its economic impact. This aspect warns us specially in the sense of understanding how the pandemic will affect the possibilities of sustaining public health policies in medium and long term. In addition, social disparities and inequities are also being intensified at the moment. This situation has an impact not only on the course of the pandemic in the different socio-cultural contexts, but also on the quality of life and survival of these populations. In this sense, we highlight the imperative to develop and implement a set of policies for social protection and support for vulnerable populations, so that we can ensure the sustainability and effectiveness of social distance measures.	5/15/2020 9:40 AM
12	Equity- how do the less advantaged populations generate the evidence and also access the resources for research	5/15/2020 9:38 AM
13	The validation of medical devices	5/15/2020 8:14 AM
14	1. The gaps between ideal and optimal and realistic.	5/15/2020 7:25 AM
15	No offense. I work hard in the day and sleep well at night in order to be prepared for my patients next day	5/15/2020 7:08 AM
16	socio-economic consequences of the response. Especially socio-economic impacts of lockdowns	5/15/2020 6:01 AM
17	Open data	5/15/2020 5:51 AM
18	The tremendous duplication of HTA and other evidence-based reviews and decision support tools and resources. Such a waste, and something our HTA and other organizations should focus on.	5/14/2020 1:02 PM
19	Nothing specific	5/14/2020 11:22 AM
20	Fast response for contingency plan	5/14/2020 9:45 AM
21	Not enough planning for good RWE collection/studies	5/14/2020 9:34 AM
22	Lack of adequate resources for the healthcare to protect themselves and combat covid-19. The	5/14/2020 7:35 AM

## Understanding the Effect of COVID-19 on HTA Globally

	effect of cultural and religious beliefs on awareness creations.	
23	vaccines, hta solutions for management optimization	5/14/2020 7:17 AM
24	The lack of innovative thinking from innovative companies. For example, Shanghai Disneyland opened and incorporated temperature screening. The evidence shows temperature screening to provide a false sense of security, <a href="https://assets.ecri.org/PDF/COVID-19-Resource-Center/COVID-19-Clinical-Care/COVID-ECRI-HTA-Temperature-Screening-2.pdf">https://assets.ecri.org/PDF/COVID-19-Resource-Center/COVID-19-Clinical-Care/COVID-ECRI-HTA-Temperature-Screening-2.pdf</a> . Yet, more and more companies are selling infrared temperature monitor systems to companies not thinking about a better way.	5/14/2020 5:14 AM
25	Growing voices for reducing processes for evidence and reduction of bias for the (unreal) sake of timely access of drugs and/or medical devices	5/14/2020 4:54 AM
26	...	5/14/2020 2:22 AM
27	Not coordinated efforts, lack of knowldege what is going on on HTA and COVID around the globe	5/14/2020 2:14 AM
28	treatmetn and vaccines	5/14/2020 1:21 AM
29	Slowness of vaccine development in combination with very low seropositivity levels in different populations, despite the drastic consequences of COVID-19.	5/14/2020 12:58 AM
30	It will be a long process of adaptation with a strong need to anticipate each phase of the pandemic even (more) from an organizational point of view. There's the need to share a debate about that kind of decisions	5/14/2020 12:40 AM
31	The continuing disruption, uncertain of an end	5/13/2020 10:27 PM
32	ethical approach to decision making related to non-covid health services that are being denied.	5/13/2020 10:18 PM
33	Decisions made without taking evidence into account, despite numerous effort for support evidence-based decisions	5/13/2020 9:12 PM
34	Lack of coordination	5/13/2020 8:36 PM
35	Prevention efforts.	5/13/2020 7:49 PM
36	Non disclosure / censoring of relevant information	5/13/2020 7:05 PM
37	Lack of good quality evidence to guide decision-making, lack of collaboration between central agencies (at the pan-canadian or provincial level) and hospital-based HTA unit to generate and disseminate the evidence.	5/13/2020 6:34 PM
38	Rapid evidence and dissemination	5/13/2020 6:29 PM
39	Trial quality	5/13/2020 5:53 PM
40	Lack of political connections to best science	5/13/2020 5:46 PM
41	–	5/13/2020 5:38 PM
42	The very low likelihood of developing an effective vaccine	5/13/2020 5:32 PM

## Q11 What do you think the primary focus on the HTA community should be in response to COVID-19?

Answered: 51 Skipped: 1



ANSWER CHOICES	RESPONSES	
Priority evidence review for most important treatments/ interventions	33.33%	17
Identification of higher-quality evidence and sources of bias for lower-quality studies	9.80%	5
Methods development for valuing treatments/interventions (e.g. changing decision thresholds)	9.80%	5
Providing up-to-date public health guidance on guidelines for patient management and supportive care, testing and tracing strategies	25.49%	13
Providing a rapid analysis on ethical, legal, social impacts relating to COVID-19 health technology assessments	5.88%	3
Other (please specify)	15.69%	8
<b>TOTAL</b>		<b>51</b>

## Understanding the Effect of COVID-19 on HTA Globally

#	OTHER (PLEASE SPECIFY)	DATE
1	A geospatial assessment of Health Services Infrastructure (number of beds, equipment, infrastructure) to help decision makers plan out health expansion projects with scientific evidence	5/17/2020 6:42 AM
2	All the above are importan depending on the audience.	5/15/2020 9:38 AM
3	Priority evidence review for most important medical devices	5/15/2020 8:14 AM
4	HTA of disruptive technology against COVID for diagnosis, treatment and prevention, using for example AI, new drugs, ICT for monitoring COVID-Patients at home, etc.	5/14/2020 9:45 AM
5	Rapid assessments including identification of bias and its impact as well as ethical, legal, social analysis	5/14/2020 2:14 AM
6	increasing activities of early , continous and iterative scientific dialogues	5/14/2020 2:05 AM
7	Attention to intellectual property barriers to access	5/13/2020 10:27 PM
8	All of the above	5/13/2020 5:53 PM

## Q12 What suggestions do you have on how HTA could be deployed to manage this current pandemic and future ones?

#	RESPONSES	DATE
1	share information and targets	5/21/2020 1:20 AM
2	Develop a pandemic Global HTA approach to streamline approval and access to treatments that are fair and equitable.	5/21/2020 12:57 AM
3	Centers like ours are speeding up the evidence review and reporting process by a factor of 5 or more. We will learn a lot from sharing lessons learned from this ultra-rapid process.	5/20/2020 7:18 PM
4	I believe that is really important to keep focus on the need of evidence based decision and to keep in mind the implications of bad use of resources that affect the tratmen of the COVID patients and also patients with other pathologies. I.e: Treatment with cloroquine is ineffective, so it could affect COVID patiens with adverse events and also It could affect patient that required not available cloroquina (like malaria patients)	5/18/2020 2:38 PM
5	I consider that nowadays HTA faces implications which we have had previously in health sector. The core of the problem that we don't have new problems, but we see how the old ones currently affect all advantages of HTA&EBM we have been collecting so many years. Foe example, officials are still neglecting scientific advise and HTA agencies recommendations. Moreover, we see how such processes are going on not only in developing dictatorship countries but even in some developed states. We also witness how some desicion-makers can be careless, particularly regarding some unproven interventions. Not surprisingly, this pandemic has definitely untied hands of politicians. Also the sad thing is that many people are still illiterate. They can't understand the way how to put face masks on. Of course, it is also the problem of EBM and those who are the part of EBM. So that the only thing which is obviously important in developing countries now is that 1. people are still in need to learn by heart simple hygenic things 2. instead of insane speeches of officials or stupid influencers, people should listen to certain professionals, some outstanding figures, not necessarily person, but really rspectful independent organisations. 3. HTA agencies should write publicly their opinion, if it is necessaty criticize. However, I barely saw that organisations could be opponents of the governments. Sadly, such inactivity or a weak will can decrease the respect of society to science in general.	5/18/2020 12:12 PM
6	Start using real world evidence as in clinical-scientific, economic and humanistic (this one specially, as both organisational and social impact) better because people must understand that science is one type of ideology/key to reading the world, has systematic/long/bureaucratic methods and guidelines and so does other productive areas. Educate people on science & technology studies, communication, public engagement and citizen science asap, please!	5/18/2020 8:24 AM
7	National Health Service Planning	5/17/2020 6:42 AM
8	Linking of horizon scanning to population health monitoring and forecast to push designing and development of appropriate interventions in advance	5/17/2020 2:37 AM
9	Many "Scientific societies" are giving their opinions on TV, radio and newspapers, many times without evidence basement. I think HTA should make it's voice to be listened	5/16/2020 6:23 AM
10	re-thinking the patient pathway organization leavereging on digital solutions in order to respond health demand. defining fast track access process for innovative drugs and innovative antibiotics and vaccines	5/15/2020 10:52 AM
11	From the public health point of view (to let out information using available avenues depending on the target population of the pandemic as regards to prevention, symptoms/signs and what to do if one suspects to have one. Supporting in provision of effective devices/tools for screening, support with provision of life saving equipment to the most in need.Working with WHO at the earliest availed opportunity offering technical assistance before escalation of the situation.	5/15/2020 9:45 AM
12	HTA can contribute to anticipate epidemic outbreaks in order to control them and provide support for the development of clinical and therapeutic guidelines. For this reason, it is important to constantly monitor the evidence that supports the decision making processes, taking into account mainly its pragmatic results. In other words, it is important that HTA is connected to practice, providing quick and objective access to information to those on the frontline of care and also to the managers responsible for the elaboration and implementation of public policies. Beside this, HTA products can inform and improve health literacy of patients and of the society as a whole. Finally, we highlight the importance of more and more inserting society in the development of this evidence and in the decision-making processes. For such, it is fundamental to develop constant mobilization and social participation actions.	5/15/2020 9:41 AM

## Understanding the Effect of COVID-19 on HTA Globally

13	HTA can contribute to anticipate epidemic outbreaks in order to control them and provide support for the development of clinical and therapeutic guidelines. For this reason, it is important to constantly monitor the evidence that supports the decision making processes, taking into account mainly its pragmatic results. In other words, it is important that HTA is connected to practice, providing quick and objective access to information to those on the frontline of care and also to the managers responsible for the elaboration and implementation of public policies. Beside this, HTA products can inform and improve health literacy of patients and of the society as a whole. Finally, we highlight the importance of more and more inserting society in the development of this evidence and in the decision-making processes. For such, it is fundamental to develop constant mobilization and social participation actions.	5/15/2020 9:40 AM
14	None at the moment, but consider the options in #11	5/15/2020 9:38 AM
15	It has an important role supporting decisions of different stakeholders	5/15/2020 8:14 AM
16	Focu sof global evidence, with local context and relevance	5/15/2020 7:25 AM
17	Support individual researchers and physicians. Everyone is happy to support governements and organization and the solo researcher and physician working in the field without any support gets neglected	5/15/2020 7:08 AM
18	HTA could help identify the most effective outbreak control measures to help us respond to future outbreaks effectively	5/15/2020 6:01 AM
19	Coordinate with other HTA, guideline and systematic review organizations to prioritize evidence reviews and development of guidance. There is too much duplication and waste of resources that could be managed by organizational collaboration within the evidence ecosystem.	5/14/2020 1:02 PM
20	Highlight patient based outcomes	5/14/2020 11:22 AM
21	Build international comission for fast reports of usable HT against pandemic situations	5/14/2020 9:45 AM
22	Education on economic analysis considering life expectancy and quality of life (rather than just lives saved)	5/14/2020 9:34 AM
23	Training of trainers on how to provide public health updated guidelines on infection control, contact tracing proper assessment/data collection and patients management	5/14/2020 7:35 AM
24	Most are out there with positive intent trying to make a true difference with this disease. Unfortunately, much of the science is low quality, misinterpreted, or exaggerated by news media in search of the panacea solution. We need organizations like HTAi, Cochrane, and ECRI to continue to independently evaluate the evidence. We then need to have influential companies like Disney incorporate and promote the work.	5/14/2020 5:14 AM
25	provide the structure and means for international exchange and colaboration of HTA bodies	5/14/2020 4:54 AM
26	I don't think that HTA has highest priority at the moment	5/14/2020 2:22 AM
27	Create a task force proactive and active in movilising quickly the HTA community when needed immediatly and making conections with all HTA community to know what is going on and share information (web site upfdating dayly)	5/14/2020 2:14 AM
28	more and earlier scientific and policy dialogues with life sciences stakeholders	5/14/2020 2:05 AM
29	improve organization	5/14/2020 1:21 AM
30	Compare the effectiveness and effects of different public health strategies applied with COVID-19. Clearly there are many differences in how countries have managed the situation and in their results. Also, one apparent target for HTA is the use of masks by the public, either all the time when out of house or just in some specific settings (e.g. in public transport). Also, vaccine developers should be supported with early dialogue so that the evidence they generate is reliable.	5/14/2020 12:58 AM
31	Promote debate on COVID-19 response models and their results. There's the need to read epidemiological, clinical, economical and organizational data together	5/14/2020 12:40 AM
32	Involve HTA early in all health policy decisions	5/13/2020 10:27 PM
33	Needs to be framed in the context to support operational decisions	5/13/2020 10:18 PM
34	To provide urgent input to the decisions and policy makers on issues regarding COVID-19 or	5/13/2020 9:12 PM

## Understanding the Effect of COVID-19 on HTA Globally

any other outbreak. A special collaborative task force can be formed once an outbreak is foreseen at international level

35	Guidance for evaluation of technologies, etc. in rapidly evolving emergent situations	5/13/2020 8:36 PM
36	Country based HTA leader shall have an open mindset and willing to work with all stakeholders. Industry and patient stigma should be drop in the midst of pandemic situation. Leveraging on stakeholders strength can accelerate the results desired. Available set of guidance will be helpful to protect information garnered and kept vested interest in check..	5/13/2020 7:49 PM
37	There should be incentives for collaboration between various HTA entities (national and hospital-based in the same jurisdiction, or international partnerships).	5/13/2020 6:34 PM
38	Extend use of cost-effectiveness analysis to public measures such as lockdown and physical distancing.	5/13/2020 6:29 PM
39	Public summaries of rapid reviews for lay audiences	5/13/2020 5:46 PM
40	–	5/13/2020 5:38 PM
41	re-setting our assumptions about our willingness to pay to very high-cost treatments for non-pandemic indications. How can we justify >\$500k per person for one treatment when we can't afford to buy enough PPE for healthcare workers?	5/13/2020 5:32 PM